Jade Biosciences (JBIO) Accounts Payables (2020 - 2026)

Jade Biosciences has reported Accounts Payables for 7 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 5666.67% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 5666.67% YoY), and the FY2025 full-year result was $2.2 million, up 66.74% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.0 million, up from $2.2 million in the prior quarter.
• The five-year high for Accounts Payables was $7.6 million in Q2 2025, with the low at $69000.0 in Q1 2025.
• Historically, Accounts Payables has averaged $3.1 million across 5 years, with a median of $2.9 million in 2022.
• Annual changes were most pronounced in 2025 — Accounts Payables slumped 97.92% — and 2026, when it surged 5666.67%.
• Jade Biosciences' Accounts Payables stood at $2.6 million in 2022, then dropped by 6.95% to $2.4 million in 2023, then plunged by 46.16% to $1.3 million in 2024, then jumped by 66.74% to $2.2 million in 2025, then soared by 84.98% to $4.0 million in 2026.
• The last three Accounts Payables figures came in at $4.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.